Ramaswamy targets promising drugs from big pharma which–because of strategy, market tastes, or politics–have stalled in clinical trials. His company Roivant buys these half-developed drugs, with the aim to rescue them drugs from the regulatory bottleneck, pushing them through the FDA.

from Forbes – Tech http://ift.tt/2lAlKpV
via IFTTT